SMS Pharmaceuticals (BOM:532815) Interest Expense : ₹-182 Mil (TTM As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is SMS Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. SMS Pharmaceuticals's interest expense for the three months ended in Dec. 2024 was ₹ -42 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₹-182 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. SMS Pharmaceuticals's Operating Income for the three months ended in Dec. 2024 was ₹ 245 Mil. SMS Pharmaceuticals's Interest Expense for the three months ended in Dec. 2024 was ₹ -42 Mil. SMS Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2024 was 5.83. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SMS Pharmaceuticals Interest Expense Historical Data

The historical data trend for SMS Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMS Pharmaceuticals Interest Expense Chart

SMS Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-111.93

-102.54

-181.57

-209.94

-226.18

SMS Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-59.53	-47.70	-46.67	-46.06	-42.03

SMS Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-182 Mil.

SMS Pharmaceuticals (BOM:532815) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SMS Pharmaceuticals's Interest Expense for the three months ended in Dec. 2024 was ₹-42 Mil. Its Operating Income for the three months ended in Dec. 2024 was ₹245 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was ₹0 Mil.

SMS Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	245.137	/	-42.03
	=	5.83

The higher the ratio, the stronger the company's financial strength is.

SMS Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SMS Pharmaceuticals Ltd (BOM:532815) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SMSPHARMA:India

Address

Plot No. 72, H.No. 8-2-334/3&4, Road. No. 5, Opposite SBI Executive Enclave, Banjara Hills, Hyderabad, TG, IND, 500034

Website

https://www.smspharma.com

SMS Pharmaceuticals Ltd is a drug manufacturing company. It is engaged in the manufacturing and sale of active pharmaceutical ingredients (API's), and their intermediates viz. Metal Acetylacetonates, Diltiazem Hydrochloride and Taxol C-13 Side Chain. Its product portfolio includes drugs for anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, anti-viral, among others.

SMS Pharmaceuticals Headlines

No Headlines